With news that the Japanese whiskey and beer giant Suntory Holdings has agreed to purchase the maker of the legendary Jim Beam bourbon for $13.6 billion, another chunk of Americana falls into foreign hands. But, in this case, perhaps, ably so.
Suntory ��which makes Yamazaki whiskey and Premium Malt's beer ��totally gets American shtick. It was, after all, among the earliest major Asian marketers to cozy-up to American celebrities to sell stuff in Japan. Way back in the "Rat Pack" heyday of the early 1970s, no less than Sammy Davis Jr., showed up in ads for Suntory brands in Japan.
Even folks who don't have the name Suntory at the tips of their tongues, probably are familiar with actor Bill Murray, whose character in the 2003 film Lost in Translation, so perfectly depicted the image of a fading American actor seeking redemption �� and a few bucks �� overseas. His most famous line from the film: "For relaxing times, make it Suntory time."
Top 10 Quality Stocks To Invest In 2015: Greengro Technologies Inc (GRNH)
GreenGro Technologies Inc., formerly Authoriszor Inc., provides management services for the planning, construction, staffing and operation of medical marijuana dispensaries, and nurseries on behalf of non-profit patient co-operatives. Through long term contracts, the Company operates non-profit centers, returning all unused patient contributions, on a pro-rata basis to each co-op member in the form of additional product. In February 2010, Authoriszor Inc. completed the acquisition of GreenGro Technologies, Inc., and CannovaHealth, a clinic management company. In September 2011, the Company acquired Vertical Hydrogarden, Inc.
Medical marijuana (medical cannabis) is an alternative method to other forms of medication used to manage or alleviate pain without the undo side-effects caused by the prescription medication being used to treat an illness. The Company stands ready to assist in patient care co-operatives throughout the United States.
Advisors' Opinion:- [By Dan Burrows]
But it doesn’t end there. Investors should run away from all OTC marijuana stocks, including Medical Marijuana (MJNA), Cannabis Science (CBIS), CannaVest (CANV), MediSwipe (MWIP) and GreenGro Technologies (GRNH). As the SEC warns:
- [By Ben Levisohn]
But, as the Huffington Post points out, most of the companies that stand to benefit are very small–they make micro caps look big–trade over the counter–good bye liquidity. That includes transaction-processing company MediSwipe (MWIPD), GreenGro Technologies (GRNH) Medbox (MDBX), which makes dispenser for high-risk drugs, and GW Pharmaceuticals (GWPRF).
10 Best Japanese Stocks To Own For 2014: Star Scientific Inc (STSI)
Star Scientific, Inc. (Star Scientific), incorporated on June 24, 1985, is engaged in the manufacturing and production of dietary supplements. The Company�� operating subsidiaries manufacture, distribute and sell consumer products and dietary supplements. Its segment includes dietary supplements. Through its Rock Creek Pharmaceuticals, Inc. (Rock Creek) subsidiary, the Company is engaged in the manufacture, sale, marketing and development of non-nicotine nutraceutical, dietary supplements: Anatabloc, for anti-inflammatory support; the manufacture, sale and marketing of a cosmetic facial cream, and the development of other nutraceuticals, dietary supplements and pharmaceutical products. On December 14, 2012, the Company voted to discontinue the manufacturing, distribution and sale of its dissolvable smokeless tobacco products, Ariva and Stonewall Hard Snuff, as of December 31, 2012. With this change it will no longer be manufacturing or selling any tobacco products.
Rock Creek Pharmaceuticals has been engaged in the development of other dietary supplements and pharmaceutical products, particularly products that have a botanical- based component and that are designed to provide nutritional support in a range of neurological conditions, including Alzheimer�� disease, Parkinson�� disease, schizophrenia, depression, and Hashimoto�� thyroiditis. Rock Creek Pharmaceuticals also has been involved in the development of a cosmetic line of products that utilizes its anatabine compound to improve the appearance of the skin. On September 10, 2012, the Company introduced Anatabloc Facial Creme into the market. As of November 9, 2012, Anatabloc was being sold through its interactive Website, a customer service center and on a consignment basis through GNC, which is a retailer of dietary supplements. The Company uses its anatabine citrate compound in its dietary supplements Anatabloc and Anatabloc Unflavored and its anatabine-based cosmetic product, Anatabloc Facial Creme.
Advisors' Opinion:- [By Jake L'Ecuyer]
Consumer goods stocks were underperformers in Tuesday's trading, up on the day by just 0.5% compared to S&P's 1.03 percent gain. Among the consumer goods stocks, shares of Star Scientific (NASDAQ: STSI) were down by more than 1 percent.
10 Best Japanese Stocks To Own For 2014: NewLead Holdings Ltd.(NEWL)
NewLead Holdings Ltd. operates as an international shipping company that owns and operates product tankers and dry bulk carriers. It operates in two segments, Wet Operations and Dry Operations. The Wet Operations segment transports various refined petroleum products simultaneously in segregated coated cargo tanks that include gasoline, jet fuel, kerosene, naphtha, and gas oil. The Dry Operations segment involves in transporting and handling bulk cargoes through ownership, operation, and trading of vessels. As of August 2, 2011, the company operated a fleet of 6 double-hull product tankers and 16 dry bulk vessels. The company was formerly known as Aries Maritime Transport Limited and changed its name to NewLead Holdings Ltd. in December 2009. NewLead Holdings Ltd. was incorporated in 2005 and is based in Athens, Greece.
Advisors' Opinion:- [By James E. Brumley]
Back in early November, yours truly penned some bullish thoughts on FreeSeas Inc. (NASDAQ:FREE), NewLead Holdings Ltd (NASDAQ:NEWL), and DryShips Inc. (NASDAQ:DRYS). While each stock has its own merits, the crux of the bullishness was ultimately rooted in the brewing rebound of the Baltic Dry Index... a reflection of the prices companies pay shippers like FreeSeas and DryShips to haul goods over the ocean.
- [By James E. Brumley]
October wasn't an easy month to own FreeSeas Inc. (NASDAQ:FREE), NewLead Holdings Ltd (NASDAQ:NEWL), DryShips Inc. (NASDAQ:DRYS), or any maritime shipper for that matter. They were all down rather sharply after heroic runups in September. DRYS fell 22% last month. NEWL slumped 41% in October. FREE gave up 44% of its value last month. What happened? After all, these same stocks were among some of the hottest names in September. In simplest terms, what happened here is what happens all too often... the market "got it right" in terms of the premise, but overdid it. Now that the dust is settling though, the undertow is kicking in again, but this time at a more reasonable/sustainable pace.
10 Best Japanese Stocks To Own For 2014: Malaysian Pacific Industries Bhd (MPI)
Malaysian Pacific Industries Berhad (MPI) is an investment holding company. The principal activities of MPI, through its subsidiaries are manufacturing, assembling, testing and sale of integrated circuits, semiconductor devices, electronic components and lead frames to customers globally. The Company�� operating geographical segments include Asia, The United States of America, and Europe. The Company's subsidiaries include Carsem (M) Sdn Bhd, Recams Sdn Bhd, Carsem Holdings Limited, Carsem Semiconductor (Suzhou) Co., Ltd, Dynacraft Industries Sdn Bhd, Carter Realty Sdn Bhd, Carter Realty Sdn Bhd and Carsem Holdings (HK) Limited. Advisors' Opinion:- [By Sofia Horta e Costa]
Michael Page International Plc (MPI) increased 1.1 percent to 490.2 pence after Goldman Sachs Group Inc. upgraded the stock to buy from neutral, saying the recruitment firm will benefit from a pick-up in the European economy.
10 Best Japanese Stocks To Own For 2014: Volkswagen AG (VLKAF.PK)
Volkswagen AG is a Germany-based automobile manufacturer. The Company develops vehicles and components, and also produces and sells vehicles, in particular Volkswagen brand passenger cars and commercial vehicles. The Company consists of two divisions: Automotive and Financial Services division. The Automotive division is responsible for the development of vehicles and engines, the production and sale of passenger cars, commercial vehicles, trucks and buses, and the genuine parts business. The Financial services division's portfolio of services includes dealer and customer services in the field of financing, leasing, direct bank, insurance and fleet business. The Company's brands include Volkswagen, Audi, Bentley, Bugatti, Lamborghini, SEAT, Skoda, Scania and Volkswagen Commercial Vehicles and each brand offers a product range from low-consumption small cars to luxury class vehicles, as well as pick ups, busses and heavy trucks in the commercial vehicle sector. Advisors' Opinion:- [By Yasir Idrees]
Nokia has already taken its Here platform to the next level after it announced the Here Connected Driving service. The Here rebranding strategy of extending Nokia's location services has helped the company reach deals with companies like BMW, Mercedes and Volkswagen (VLKAF.PK) and Connected Driving is what takes this to the next level.
10 Best Japanese Stocks To Own For 2014: Supernus Pharmaceuticals Inc (SUPN)
Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�� two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.
Supernus�� Late-Stage Neurology Portfolio
SPN-538 is an oral once-daily extended release topiramate product for the treatment of epilepsy. Topiramate is marketed by Johnson & Johnson under the brand name Topamax and is available in a generic form. As of December 31, 2009, Topiramate was available only in immediate release form and is indicated for monotherapy and adjunctive therapy of epilepsy and for the treatment of migraine. It works by enhancing the inhibitory effect of the Gamma-Aminobutyric Acid (GABA) neurotransmitter that regulates neuronal excitability throughout the nervous system, blocking the excitatory effect of the glutamate neurotransmitter, blocking the sodium channel and inhibiting the carbonic anhydrase enzyme.
Epliga is an oral once-daily extended release formulation of oxcarbazepine. As of December 31, 2009, Epliga was in Phase III trials. Oxcarbazepine is marketed by Novartis under the brand name Trileptal and is available in a generic form. Trileptal is indicated for monotherap! y and adjunctive therapy of epilepsy. Oxcarbazepine is an active voltage-dependent sodium channel blocker.
Supernus�� Psychiatry Portfolio
SPN-810 (molindone hydrochloride) is a treatment for impulsive aggression in patients with ADHD. As of December 31, 2009, it was in Phase II. SPN-810 is based on molindone hydrochloride. As of December 31, 2009, the Company had completed four clinical trials for SPN-810, including a Phase IIa trial, in which it tested the safety and tolerability of immediate release molindone hydrochloride in children with ADHD who suffer from serious persistent conduct problems. This open-label, dose-ranging trial randomized 78 children, 6-12 years of age, into one of four treatment groups, which were given four different doses of immediate release molindone hydrochloride, between 10 milligram and 40 milligram per day, depending on weight, three times a day over a six-week treatment period, after 2-5 weeks of titration. SPN-810 was well tolerated in the trial with no clinically meaningful changes in standard hematology, clinical chemistry values, vital signs or electrocardiogram results. SPN-810 also showed improvements on the primary and secondary outcome measures, such as conduct problem and ADHD scales, across all four treatment groups. SPN-812 is a non-stimulant treatment for ADHD. As of December 31, 2009, SPN-812 was in Phase II. SPN-812 is a selective norepinephrine reuptake inhibitor.
Supernus�� Technology Platforms
The Company has a long track record of developing products by applying technologies to known drugs to improve existing therapies and to enable the treatment of new indications. Supernus�� main technology platforms include: Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The Company�� technologies have been used in the approved and marketed products, including Carbatrol (carbamazepine), Equetro (carbamazepine), Adderall XR (mixe! d ampheta! mine salts), Sanctura XR (trospium chloride), Oracea (doxycycline) and Intuniv (guanfacine).
Advisors' Opinion:- [By Wallace Witkowski]
Shares of Supernus Pharmaceuticals (SUPN) �jumped 20% after hours Monday after a drug on which the firm collaborated received Food and Drug Administration approval.
- [By Monica Gerson]
Supernus Pharmaceuticals (NASDAQ: SUPN) is expected to post a Q4 loss at $0.55 per share on revenue of $7.78 million.
Geron (NASDAQ: GERN) is projected to post a Q4 loss at $0.07 per share on revenue of $350.00 thousand.
- [By Monica Gerson]
Supernus Pharmaceuticals (NASDAQ: SUPN) confirmed the FDA approval of its partner's heart blood-pressure treatment. Supernus shares jumped 18.24% to $8.75 in after-hours trading.
10 Best Japanese Stocks To Own For 2014: Eaton Vance Tax-Managed Diversified Equity Income Fund (ETY)
Eaton Vance Tax-Managed Diversified Equity Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The Fund invests primarily in a diversified portfolio of common stocks. The Fund will invest at least 80% of its total assets in a combination of dividend paying common stocks, and common stocks the value of which is subject to covered written index call options. It seeks to generate current earnings in part by writing (selling) stock index call options on the S&P 500 Index and investing in dividend-paying common stock. The Fund invests in sectors, such as financials, energy, information technology, industrials, healthcare, consumer staples, telecommunication services, consumer discretionary, materials and utilities.
The Fund�� investment advisor is Eaton Vance Management (EVM). Its sub-advisor is Rampart Investment Management. The Fund may invest in Cash Management Portfolio, an affiliated investment company managed by Boston Management and Research (BMR), a subsidiary of EVM.
Advisors' Opinion:- [By Robert Carlson]
This recommended fund is Eaton Vance Tax-Managed Diversified Equity Income (ETY). The options that the fund writes give buyers the right to buy the stocks from the fund at fixed prices by a certain date.
No comments:
Post a Comment